BioAtla, Inc. Nasdaq Delisting Affirmed by Listing Council

What Happened
BioAtla, Inc. (BCAB) reported on Form 8-K that on August 26, 2026 the Nasdaq Listing and Hearing Review Council affirmed a prior Nasdaq Hearings Panel decision to delist the company's common stock. The Panel’s original delist determination (received Feb 6, 2026) cited non-compliance with the $1.00 minimum bid price requirement (Nasdaq Rule 5550(a)(2)) and the $2.5 million stockholders’ equity standard (Nasdaq Rule 5550(b)(1)). The Listing Council had earlier stayed any suspension while it reviewed the matter; unless the Nasdaq Board requests further review, Nasdaq trading is expected to be suspended at the open on August 31, 2026 and a Form 25-NSE will be filed to remove the listing.

Key Details

• Filing: Current Report on Form 8-K dated August 28, 2026 reporting the Listing Council decision issued Aug 26, 2026.
• Reasons: Failure to meet the $1.00 bid-price rule and failure to demonstrate $2.5M stockholders’ equity (despite prior compliance with the $35M market value alternative for 69 consecutive trading days).
• Timing/next steps: Trading is expected to be suspended on Nasdaq at the open Aug 31, 2026 unless the Nasdaq Board calls the matter for review; the company expects the stock may become eligible to trade on the OTC Markets under ticker BCAB.
• Company actions: BioAtla began a formal strategic review process in March 2026; no transaction is assured.

Why It Matters
A Nasdaq delisting and potential move to OTC Markets can materially affect liquidity, trading volume and share price—retail investors may find it harder to buy or sell BCAB shares and spreads may widen. The company also reiterated forward-looking risks in the filing, including potential funding needs and going concern considerations, and noted there is no assurance the ongoing strategic review will produce a transaction. Investors should monitor upcoming Nasdaq decisions, any Form 25-NSE filing, and company updates about the strategic process and financing.